CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy), that is, the chimeric antigen receptor T cell immunotherapy. The therapy is a lot of years, but there has been only in recent years to improve the clinical use of novel cell therapies. In acute leukemia and non-Hodgkin’s lymphoma has a significant effect, it is considered one of the most promising cancer treatment. As with all technologies, CAR-T technology has gone through a long process of evolution, it is in the evolution of this series, CAR-T technology matured.

In recent years, CAR-T immunotherapy in addition to being used to treat acute leukemia and non-Hodgkin’s lymphoma addition, the improved, also used to treat solid tumors, autoimmune diseases, HIV infection and other diseases and transplant rejection, with broader application space.